Latest news about Aurobindo Pharma
Aurobindo Pharma subsidiary Apitoria's Unit-IV API facility clears US FDA inspection
Aurobindo Pharma
1,679.80
+11.40(+0.68%)
Company Performance:
View Company Insights1D+0.68%
1M+1.93%
6M+30.63%
1Y+59.94%
5Y0.00%
More news about Aurobindo Pharma
03Sept 26
Rumors circulate about Aurobindo Pharma promoter block deal
Rumors suggest a potential block deal involving Aurobindo Pharma's promoter. No official confirmation or disclosure has been made by the company. SEBI regulations require disclosure of material information impacting prices. Market speculation lacks supporting financial data or official statements.
01Sept 26
Aurobindo Pharma incorporates Avogent Lifesciences for manufacturing and marketing
Aurobindo Pharma incorporated Avogent Lifesciences Private Limited on August 31, 2026. The entity is a wholly owned subsidiary of Apitoria Pharma Private Limited. Initial share capital is ₹5 crore divided into 50,00,000 equity shares. The subsidiary will handle manufacturing and marketing operations in India and abroad. No regulatory approvals were required for the incorporation.
31Aug 26
Aurobindo launches generic Advair Diskus in US market
Lannett Company LLC launched generic Advair Diskus in the US on August 31, 2026. Product available in 100/50 mcg and 250/50 mcg strengths. First commercial inhalation product from Aurobindo's pipeline. Targets asthma and COPD patients with generic alternative.
31Aug 26
US FDA completes Apitoria Pharma Unit-VI inspection with three observations
US FDA completed inspection of Apitoria Pharma Unit-VI. Three procedural observations were noted by regulators. Aurobindo Pharma must address findings within stipulated time.
28Aug 26
Aurobindo Pharma AGM results: ₹4 dividend confirmed, K. Nithyananda Reddy reappointed amid dissent
All six resolutions at Aurobindo Pharma's 39th AGM passed with requisite majority. Interim dividend of ₹4 per share for FY26 confirmed with 99.99% shareholder support. Reappointment of K. Nithyananda Reddy faced 5.87% dissent, mainly from public institutions. Audited standalone and consolidated financial statements for FY26 adopted unanimously. Total paid-up equity capital stands at ₹57,53,77,895 as on August 20, 2026.
25Aug 26
Aurobindo Pharma to attend Goldman Sachs Asia Leaders Conference
Aurobindo Pharma officials will attend the Goldman Sachs Asia Leaders Conference in Hong Kong. Meetings scheduled for September 1-2, 2026, include both one-on-one and group sessions. The company confirmed no unpublished price-sensitive information will be discussed. Schedule is subject to change based on investor or company exigencies.
25Aug 26
Aurobindo Pharma to host investor meet at Elara India Dialogue 2026
Aurobindo Pharma will host investors at the Ashwamedh – Elara India Dialogue 2026. The event is scheduled for September 1, 2026, in Mumbai. Meetings will run from 9:00 am to 5:00 pm. No unpublished price sensitive information will be discussed.
24Aug 26
Aurobindo Pharma subsidiary Lannett faces four US FDA compliance issues
Aurobindo Pharma's subsidiary Lannett Company LLC received four compliance observations from the US FDA. The findings emerged following a US FDA inspection of the Lannett facility. The development signals regulatory scrutiny at the subsidiary level.
21Aug 26
US FDA inspection of Auropeptides Ltd concludes with one finding
US FDA completed an inspection of Auropeptides Ltd, linked to Aurobindo Pharma. The inspection concluded with one finding. No further details on the nature or classification of the finding were disclosed.
14Aug 26
Eugia Pharma Specialities receives US FDA warning letter
Eugia Pharma Specialities, a unit of Aurobindo Pharma, has received a warning letter from the US FDA. The company has stated that current US supplies remain unaffected. The unit accounts for about 2% of Aurobindo Pharma's total revenue, limiting the direct financial exposure from this regulatory development.
13Aug 26
Aurobindo Pharma incorporates Auropharm Overseas for global ops
Aurobindo Pharma Limited has incorporated Auropharm Overseas Limited as a wholly owned subsidiary in India. The new entity, established on August 13, 2026, will manage manufacturing and marketing operations in India and foreign markets. The initial share capital subscription is ₹10 lakh via cash consideration, with no promoter group interest involved.
07Aug 26
Aurobindo Pharma Q1 Results: Net profit rises 25% YoY to ₹10,320 crore
Aurobindo Pharma reported Q1FY26 consolidated net profit of ₹10,320.3 million, up 25.2% YoY, with revenue rising 16.3% to ₹91,503.5 million. Standalone net profit grew 31.9% to ₹7,372.2 million despite a slight dip in standalone revenue. EPS increased to ₹17.86 consolidated and ₹12.75 standalone.
06Aug 26
Aurobindo Pharma joins Nuvama India Conference 2026 in Singapore
Aurobindo Pharma Limited will engage with investors at the Nuvama India Conference 2026 in Singapore and Hong Kong from August 11 to 13, 2026. The meetings will occur between 09:00 AM and 06:00 PM (GMT +8), with no unpublished price-sensitive information to be shared.
06Aug 26
Aurobindo Pharma Q1 profit rises 25% to ₹1,032 crore on Europe surge
Aurobindo Pharma reported a 25.2% YoY increase in Q1FY27 net profit to ₹1,032 crore, driven by strong performance in Europe and the US. Revenue grew 16.3% to ₹9,150 crore, with operating EBITDA margins expanding by 60 bps. The company generated US$ 98 million in free cash flow despite significant capital outflows for the Lannett acquisition and share buybacks.
06Aug 26
Aurobindo Pharma Latest Results: Eugia's FY27 Revenue Target Set at $500 Million
Aurobindo Pharma expects its subsidiary Eugia to reach $500 million in revenue by FY27. The target highlights the strategic focus on Eugia's injectable business segment. The announcement reflects management's confidence in the unit's growth potential within the pharmaceutical industry.
06Aug 26
Aurobindo Pharma Q1 profit rises 32%, EBITDA margin expands to 23.07%
Aurobindo Pharma reported a 32% YoY rise in Q1 consolidated net profit to ₹10.33 billion, with revenue climbing to ₹91.5 billion and EBITDA margin expanding 270 bps to 23.07%, aided by the Lannett Company LLC acquisition. The Board approved the amalgamation of Eugia Steriles and Eugia SEZ into Eugia Pharma Specialities to streamline operations, while the company also made new subsidiary incorporations and a stake acquisition during the quarter.
04Aug 26
Aurobindo Pharma shares FY26 Annual Report web-link ahead of AGM
Aurobindo Pharma Limited disclosed the web-link for its FY26 Integrated Annual Report on August 4, 2026, ahead of its 39th AGM on August 27, 2026. Shareholders are urged to update KYC details to receive electronic dividends. The AGM agenda includes reappointing two directors and appointing M/s. RPR & Associates as Secretarial Auditor.
03Aug 26
Aurobindo Pharma submits FY26 sustainability report with ESG metrics
Aurobindo Pharma Limited filed its FY26 BRSR report on August 3, 2026, disclosing consolidated ESG metrics. Key highlights include an 18.4% renewable energy share, 100% non-hazardous waste recycling, and a workforce of over 46,000. The report covers operations in 151 countries and outlines 2030 sustainability targets, with reasonable assurance provided by Sharp & Tannan Associates.
03Aug 26
Aurobindo Pharma FY26 Results: Revenue up 2.2% to ₹111,717 Cr
Aurobindo Pharma reported FY26 standalone revenue of ₹111,717 million, up 2.2% YoY, with consolidated revenue rising 6.1% to ₹336,531 million. Net profit increased to ₹35,030 million. Europe formulations surged 23.4% to €1,007 million, offsetting a 2.7% drop in US sales. The company declared an interim dividend of ₹4.00 per share and completed a ₹8,000 million share buyback.
29Jul 26
Aurobindo Pharma Q1 Results: Earnings call scheduled for Aug 6
Aurobindo Pharma Limited scheduled an earnings call for August 6, 2026, to discuss Q1FY27 results. The call, compliant with SEBI Regulation 30(2), allows investors to review unaudited financials for the quarter ended June 30, 2026. Management will provide insights into performance drivers during the session.
26Jul 26
Aurobindo Pharma signs royalty-free alimtravir license with MSD for 129 LMICs
Aurobindo Pharma has entered a non-exclusive, royalty-free voluntary licensing agreement with MSD to manufacture and supply generic alimtravir to 129 low- and middle-income countries. Announced on July 24, 2026, the deal is notable for being executed before the completion of Phase 3 trial enrollment, a first in HIV prevention. This allows for early planning of scale-up operations to address global HIV diagnosis needs.
23Jul 26
Aurobindo Pharma subsidiary acquires 80% stake in A1 Biochem for USD 17M
Apitoria Pharma, a subsidiary of Aurobindo Pharma, acquired an 80% stake in A1 Biochem Group for USD 17 million to expand its CRDMO capabilities. The deal integrates A1 Biochem's CRO services, including custom synthesis and analytical development, with Apitoria's existing API manufacturing business. A1 Biochem reported a turnover of INR 1,024.42 Mn and EBITDA of INR 465.46 Mn in FY25-26.
22Jul 26
Aurobindo Pharma unit secures Brazil ANVISA approval for facility
CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma, secured ANVISA approval for its biosimilars manufacturing facility in Hyderabad after a successful GMP inspection from May 11 to May 15, 2026. The approval covers biological API and sterile products, including four specific biosimilar products, and strengthens the company's market reach in Brazil and Latin America.
13Jul 26
Aurobindo Pharma subsidiary incorporates PT Auro Pharm Indonesia
Aurobindo Pharma's wholly owned step-down subsidiary, PT Aurogen Pharma Indonesia, incorporated PT Auro Pharm Indonesia on July 1, 2026, to expand manufacturing operations. The entity is fully owned via a cash subscription of IDR 20,000,000,000 divided into 2000 shares.
10Jul 26
Citi Maintains Sell Rating on Aurobindo Pharma, Raises Target Price to ₹1,270 from ₹1,020
Citi has maintained a Sell rating on Aurobindo Pharma while raising its target price to ₹1,270 from ₹1,020, citing valuations that have risen to 2 standard deviations above historical averages following a recent rally. The brokerage notes that FX tailwinds and PLI benefits are already priced in, with the stock trading at 20x FY28E EPS. Growth is expected to slow in FY28–29 due to limited pipeline visibility, weaker Lannett prospects, and a modest long-term PAT CAGR, making the risk-reward unattractive at current levels.
03Jul 26
Aurobindo Pharma completes transfer of domestic branded generic business to Auropharm Limited
Aurobindo Pharma has transferred its domestic branded generic pharmaceutical formulations products business to wholly owned subsidiary Auropharm Limited effective July 1, 2026. The slump sale transaction, agreed upon in April 2026, consolidates domestic operations under the subsidiary.
01Jul 26
Aurobindo Pharma USA completes Lannett acquisition
Aurobindo Pharma USA Inc, a wholly owned subsidiary of Aurobindo Pharma Limited, has completed the acquisition of Lannett Company, Inc., USA following U.S. Federal Trade Commission approval. Effective June 29, 2026, Lannett operates as a wholly owned subsidiary, adding over 400 employees to the organization. The integration focuses on maintaining access to critical medications and delivering long-term value to stakeholders.
29Jun 26
Aurobindo Pharma US FDA Inspection Concludes With Two Observations, Response to Be Filed Within Deadline
Aurobindo Pharma completed a US FDA inspection at one of its facilities, with the regulatory authority recording two observations. As per standard protocol, these observations are documented on a Form 483, and the company is required to file its response within the stipulated timeframe for further regulatory review.
26Jun 26
Aurobindo Pharma acquires 26% stake in Swarnaakshu Solar for Rs 52 lakhs
Aurobindo Pharma has completed the acquisition of a 26% equity stake in Swarnaakshu Solar Power Private Limited with an initial investment of Rs 52 lakhs. The company executed a solar power purchase agreement to procure power for captive consumption, aligning with the Government of Telangana's captive power policy. The total approved investment is Rs 10.40 crores, with the balance to be disbursed based on project progress.
23Jun 26
Aurobindo Pharma USA gets FTC nod for $250m Lannett buy
Aurobindo Pharma USA Inc received approval from the U.S. Federal Trade Commission to acquire Lannett Company LLC for $250 million on a cash-free, debt-free basis. The transaction, expected to close by June 2026, includes a manufacturing facility in Seymour, Indiana with a capacity of 4 billion doses annually. The acquisition is anticipated to be immediately accretive to earnings and generate cost efficiencies.
22Jun 26
Bernstein, HSBC Weigh In on Aurobindo Pharma Amid FDA OAI Classification
Aurobindo Pharma's Eugia Unit-III has received a US FDA OAI classification following an inspection with 11 findings. Bernstein maintains a Market Perform rating with a TP of ₹1,498, warning of ~35 frozen ANDAs and a 3–3.5% FY27 EPS drag. HSBC retains a Buy rating with a TP of ₹1,580, highlighting the Lannett acquisition as a driver toward USD 2 billion in US sales by FY27, with gAdvair launch and Pen G and China plant cost breakeven as additional catalysts.
20Jun 26
Aurobindo Pharma promoters disclose no new encumbrances as of March 31, 2026
Aurobindo Pharma Limited confirmed in a regulatory filing that its promoters have not created any new encumbrances on their shares as of March 31, 2026, aside from those previously disclosed. The declaration, made by K. Nithyananda Reddy on behalf of the promoter group, adheres to SEBI regulations regarding substantial acquisition of shares. The filing details the promoter group's total holding of 30,09,48,721 shares, which constitutes 51.82% of the company's total share capital.
10Jun 26
Aurobindo Pharma to attend Goldman Sachs investor meet
Aurobindo Pharma Limited officials will participate in a group investor meeting organized by Goldman Sachs on June 12, 2026, in Hyderabad. The meeting, part of the Goldman Sachs CRO/CDMO Tour, is scheduled from 03:30 PM to 05:00 PM IST. The company stated that no unpublished price sensitive information (UPSI) will be discussed during the interactions, though the schedule remains subject to change.
06Jun 26
Aurobindo Pharma officials to attend UBS virtual investor meet
Aurobindo Pharma Limited announced that its officials will participate in the UBS - Virtual Generics and Biosimilar Day, a virtual investor meeting scheduled for June 10, 2026, from 19:00 to 20:00 IST. The company confirmed that no unpublished price sensitive information will be discussed during the event. The disclosure was submitted to the National Stock Exchange of India Limited and BSE Limited on June 5, 2026, by B. Adi Reddy, Company Secretary.
05Jun 26
Aurobindo Pharma Receives Final US FDA Approval for Tofacitinib Tablets in 5 mg and 10 mg Strengths
Aurobindo Pharma has received final US FDA approval for Tofacitinib Tablets in 5 mg and 10 mg strengths, marking a key regulatory milestone. The approval underscores the company's commitment to FDA quality standards and further strengthens its generics pipeline for the US market.
04Jun 26
Aurobindo Pharma Inaugurates TheraNym Biologics Facility With MSD as Anchor Customer
Aurobindo Pharma launched TheraNym, one of India's largest dedicated biologics CMO facilities, in Borapatla, Telangana on June 3, 2026, with MSD as anchor customer. The facility features 15 KL bioreactors, advanced downstream processing, aseptic fill-finish, and quality control labs, marking the company's strategic entry into biologics contract manufacturing to serve global pharma supply chains.
04Jun 26
Aurobindo Pharma to attend ICICI Securities conference on June 8
Aurobindo Pharma Limited officials will participate in the ICICI Securities India Investor Conference on June 8, 2026, in Mumbai. The meeting, scheduled from 10:00 to 18:00 IST, involves in-person and group interactions with investors. The company confirmed that no unpublished price sensitive information will be discussed during the event.
28May 26
Aurobindo Pharma attends BofA 2026 India Conference on June 2
Aurobindo Pharma Limited announced its participation in the BofA 2026 India Conference scheduled for June 2, 2026, in Mumbai. Company officials will conduct in-person and group meetings between 09:00 AM and 06:00 PM IST. The company confirmed that no unpublished price sensitive information will be disclosed during these interactions.
28May 26
Aurobindo Pharma to attend Investec US Pharma meeting on June 4
Aurobindo Pharma officials will attend the Investec US Pharma and Healthcare Bus Tour 7.0 in New Jersey on June 4, 2026, to update investors on operations. The company confirmed no unpublished price sensitive information will be shared during the meeting.
25May 26
US FDA Classifies Aurobindo Unit as OAI
Aurobindo Pharma Limited disclosed that the US FDA classified Unit-I of its subsidiary Eugia Pharma Specialities Limited as OAI following an inspection from February 16 to February 27, 2026. The inspection resulted in four observations, with the formal communication received on May 23, 2026. The company confirmed that there is no impact on its financials or operations due to this action.
25May 26
Aurobindo Pharma Draws Mixed Analyst Views; DAM Capital, Goldman Sachs, Nuvama Maintain Buy
Aurobindo Pharma has received Buy ratings from DAM Capital (₹1767), Goldman Sachs (₹1550), Nuvama (₹1680), and BofA Securities (₹1700), with brokerages citing the Lannett deal, Pen-G ramp-up, Europe growth, and biosimilar investments as key drivers. CLSA, however, downgraded the stock to Hold at ₹1490, flagging higher opex and margin pressure, with meaningful growth expected only from FY28 onwards.
23May 26
Aurobindo Pharma Unit Launches French Subsidiary
Aurobindo Pharma Limited announced that its wholly owned step-down subsidiary, Agile Pharma BV, has incorporated a new entity in France named Arrow Pharma Production SAS. The new subsidiary, established on May 21, 2026, will focus on the manufacturing of generic formulations. The authorized capital of the entity is 100,000 EUR, divided into 100,000 shares of 1 EUR each, fully owned by Agile Pharma BV.
23May 26
Aurobindo Pharma FY26 Net Profit Rises to ₹3,503 Cr
Aurobindo Pharma announced its audited financial results for the quarter and year ended March 31, 2026, reporting a consolidated net profit of ₹3,503 crore for FY26, a slight increase from the previous year. Revenue grew by 6.1% annually to ₹33,653 crore, while Q4 revenue rose 5.6% to ₹8,853 crore. The company published these results in newspapers on May 23, 2026, and has guided for EBITDA margins above 21% in FY27, driven by improved operational efficiency.
22May 26
Aurobindo Pharma Appoints RPR & Associates as Secretarial Auditor
Aurobindo Pharma Limited has accepted the resignation of M/s. MRR & Associates as Secretarial Auditor effective May 22, 2026, due to health issues. The board has appointed M/s. RPR & Associates as the new Secretarial Auditors for a term of five consecutive years from FY 2026-27 to FY 2030-31, pending shareholder approval.
19May 26
Aurobindo Pharma Extinguishes 54,23,728 Equity Shares Under ₹800 Crore Buyback Programme
Aurobindo Pharma Limited extinguished 54,23,728 equity shares on May 14, 2026, under its tender offer buyback conducted at ₹1,475 per share for an aggregate amount not exceeding ₹800,00,00,000. All extinguished shares were in dematerialised form, with confirmations received from both NSDL and CDSL. The company's paid-up share capital has been reduced from 58,08,01,623 equity shares to 57,53,77,895 equity shares of ₹1/- each following the extinguishment. The process was carried out in compliance with the SEBI (Buy-Back of Securities) Regulations, 2018.
18May 26
Telangana High Court Dismisses Aurobindo Pharma Promoters' Writ Petition Against SEBI's Profit Deposit Directive
The Telangana High Court dismissed a writ petition filed by Aurobindo Pharma's promoter group members — Mr. P. V. Ramprasad Reddy, Ms. P. Suneela Rani, Mr. Kambam Prasad Reddy, and Trident Chemphar Limited — challenging SEBI's October 2020 directive to deposit Rs. 6.53 crores in trading profits along with 12% per annum interest into the Investor Protection and Education Fund. The order, dated May 6, 2026, has no impact on Aurobindo Pharma's financials or operations, and the petitioners are evaluating further legal options.
16May 26
Aurobindo Pharma Subsidiary CuraTeQ Biologics Secures CDSCO Marketing Authorisation for Bevqolva® Bevacizumab Biosimilar
Aurobindo Pharma's subsidiary CuraTeQ Biologics has received CDSCO marketing authorisation (Form CT 23) for Bevqolva®, a bevacizumab biosimilar. This approval enables CuraTeQ Biologics to market the biosimilar product in India. The development marks a notable regulatory achievement for Aurobindo Pharma's biologics arm, reinforcing its presence in the oncology biosimilars space.
14May 26
Aurobindo Pharma Schedules Q4FY26 Board Meeting on May 21 and Earnings Call on May 22
Aurobindo Pharma has scheduled a Board of Directors meeting on May 21, 2026 to approve standalone and consolidated audited financial results for Q4 and FY26, followed by an Analyst/Investor Earnings Call on May 22, 2026 at 8:30 AM IST via Zoom. The Trading Window, closed since April 1, 2026, will reopen on May 24, 2026 after the customary 48-hour period post results declaration.
13May 26
Aurobindo Pharma Records ₹30.08 Crore Block Trade on NSE at ₹1,496.50 Per Share
Aurobindo Pharma witnessed a block trade on the NSE involving approximately 2,00,977 shares executed at ₹1,496.50 per share, with the aggregate deal value amounting to ₹30.08 crores. Such large-scale block trades are typically associated with institutional investors and may indicate portfolio rebalancing or strategic position changes by major market participants.
08May 26
Aurobindo Pharma Completes Buyback of 54,23,728 Equity Shares at ₹1,475 Per Share for ₹800 Crore
Aurobindo Pharma Limited has completed its buyback of 54,23,728 equity shares at ₹1,475 per share, utilizing ₹799,99,98,800 (excluding transaction costs) out of the maximum buyback size of ₹800,00,00,000. The buyback, conducted via the tender offer route, was oversubscribed approximately 5.43 times, with KFin Technologies Limited recording 26,568 valid bids for 2,94,73,022 equity shares. Settlement was completed by Indian Clearing Corporation Limited on May 7, 2026, with the extinguishment of accepted shares expected on or before May 18, 2026. Post-buyback, the company's issued and paid-up share capital stands at 57,53,77,895 equity shares, subject to formal extinguishment.
07May 26
Aurobindo Pharma Unit-VII Receives US FDA Voluntary Action Indicated Classification
Aurobindo Pharma Limited's Unit-VII oral solid dosage manufacturing facility in Telangana has received a Voluntary Action Indicated (VAI) classification from the US FDA, following an inspection conducted from January 28 to February 10, 2026, which issued 9 Form 483 observations. The FDA has formally closed the inspection, and the development was disclosed under SEBI Regulation 30 by Company Secretary B. Adi Reddy on May 6, 2026.
05May 26
Aurobindo Pharma Intimates Resignation of Dr. Sanjay Chaturvedi as CEO of Subsidiary Apitoria Pharma
Aurobindo Pharma Limited has disclosed the resignation of Dr. Sanjay Chaturvedi as Chief Executive Officer of Apitoria Pharma Private Limited, its wholly owned subsidiary, effective May 4, 2026. Dr. Chaturvedi cited his intention to pursue a different opportunity as the reason for stepping down. The intimation was filed with both NSE and BSE in compliance with Regulation 30, and was signed by Company Secretary B. Adi Reddy.
02May 26
Aurobindo Pharma's CuraTeQ Biologics Receives Health Canada NOC for Bevqolva
Aurobindo Pharma's wholly owned subsidiary CuraTeQ Biologics has received Notice of Compliance from Health Canada for its bevacizumab biosimilar Bevqolva™, announced on May 1, 2026. The product, available in 100 mg and 400 mg formulations, treats multiple cancers including colorectal and lung by inhibiting angiogenesis. CuraTeQ previously launched Bevqolva™ commercially in the UK in 2025 and has the product under EMA review for European market access.
30Apr 26
Aurobindo Pharma Announces Retirement of Chief Business Officer, Emerging Markets
Aurobindo Pharma has disclosed the retirement of Mr. N. Ravi Kiran, Chief Business Officer, Emerging Markets, effective from the close of business hours on April 30, 2026. The announcement was made pursuant to Regulation 30 of the SEBI Listing Regulations. The company has provided the required details in an annexure to the disclosure.
23Apr 26
Aurobindo Pharma Receives USFDA Approval for Glycerol Phenylbutyrate Drug
Aurobindo Pharma has secured USFDA approval for Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per ml, targeting a US$ 50.2 million market opportunity. The product, manufactured at Unit-III facility, treats urea cycle disorders and expands the company's ANDA portfolio to 579 total approvals.
23Apr 26
Aurobindo Pharma Buyback Opens at ₹1,475 Per Share for Up to 54,23,728 Equity Shares
Aurobindo Pharma Limited has commenced its buyback offer for up to 54,23,728 equity shares at ₹1,475 per share, aggregating to ₹800,00,00,000. The offer opened on April 23, 2026, and closes on April 29, 2026. Eligible shareholders include small shareholders with an entitlement of 7 equity shares out of every 61 held, and general category shareholders entitled to 2 equity shares out of every 249 held as on the record date of April 17, 2026. The letter of offer was dispatched electronically on April 21, 2026. Shareholders can check their entitlement through the registrar's website. Axis Capital Limited serves as the manager to the offer, while KFin Technologies Limited is the registrar.
21Apr 26
Aurobindo Pharma Records Rs. 33.11 Crore Block Trade on NSE
Aurobindo Pharma Ltd. executed a significant block trade on NSE involving 241,320 shares at Rs. 1371.90 per share, totaling Rs. 33.11 crores. The transaction represents substantial institutional trading activity in the pharmaceutical company's stock, indicating strong investor interest and potential portfolio adjustments by large market participants.
20Apr 26
Aurobindo Pharma Gets USFDA Approval for Extended-Release Cough Suspension
Aurobindo Pharma has secured USFDA approval for its extended-release dextromethorphan polistirex oral suspension, targeting a US$ 138.00 million cough medication market. The OTC product will be manufactured at APL Healthcare's Unit-IV facility and is scheduled for launch in Q2FY27, marking the company's 580th ANDA approval from the USFDA.
16Apr 26
Macquarie Maintains Underperform Rating on Aurobindo Pharma Despite TheraNym's Expanded Merck Deal
Macquarie has maintained its Underperform rating on Aurobindo Pharma with a target price of ₹1,050, despite TheraNym Biologics' expanded partnership with Merck involving a $150-175 million greenfield facility with 60,000L bioreactor capacity. While the deal validates biologics capabilities, analysts expect meaningful financial benefits only in 3-4 years.
09Apr 26
Aurobindo Pharma Submits SEBI Compliance Certificate for Quarter Ended March 31, 2026
Aurobindo Pharma Limited filed its mandatory SEBI compliance certificate under Regulation 74(5) for the quarter ended March 31, 2026, on April 9, 2026. The certificate confirms proper reporting of dematerialized and rematerialized securities to all relevant stock exchanges. Supporting documentation was provided by KFin Technologies Limited, the company's Registrar and Transfer Agent, with certificates dated April 1, 2026.
08Apr 26
Aurobindo Pharma Publishes Detailed ₹800 Crore Share Buyback Announcement
Aurobindo Pharma has released detailed regulatory documentation for its ₹800 crore share buyback program, covering 54.23 lakh shares at ₹1,475 each. The announcement provides extensive implementation details, regulatory compliance confirmations, and outlines the tender offer process through BSE with special provisions for small shareholders.
08Apr 26
Aurobindo Pharma Gets USFDA Final Approval For Dapagliflozin Tablets Generic
Aurobindo Pharma has received USFDA final approval for its Dapagliflozin Tablets in 5mg and 10mg strengths, serving as a generic equivalent to AstraZeneca's Farxiga. The company secured 180 days of shared generic drug exclusivity by being among the first ANDA applicants with paragraph IV certification. This approval targets a substantial US$ 10.2 billion diabetes treatment market and brings the company's total ANDA approvals to 579, including 554 final approvals and 25 tentative approvals.
08Apr 26
Aurobindo Pharma Receives USFDA Approval for Diabetes Drug with 180-Day Market Exclusivity
Aurobindo Pharma Limited received USFDA approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in four strengths, with an estimated market size of US$ 514 million. The company secured 180 days of shared generic drug exclusivity as one of the first ANDA applicants with paragraph IV certification. Products will be manufactured at Unit-IV of APL Healthcare Limited and launched immediately, adding to the company's portfolio of 579 ANDA approvals from USFDA.
07Apr 26
Aurobindo's CuraTeQ Biologics Reports Positive Phase 3 Results for Omalizumab Biosimilar
Aurobindo Pharma's subsidiary CuraTeQ Biologics achieved positive Phase 3 results for its omalizumab biosimilar BP11, demonstrating high comparability to reference product Xolair in a 608-patient trial across multiple countries. The study met all primary endpoints with confidence intervals within predefined margins, supporting regulatory submissions to EMA and FDA planned by end of Q2 2026 for chronic spontaneous urticaria, allergic asthma, and chronic rhinosinusitis indications.
06Apr 26
Aurobindo Pharma Approves ₹800 Crore Share Buyback at ₹1,475 Per Share
Aurobindo Pharma's board has approved a comprehensive share buyback program worth ₹800.00 crores, involving repurchase of up to 54,23,728 equity shares at ₹1,475.00 per share through tender offer route. The buyback represents 0.93% of total paid-up equity capital with record date scheduled for April 17, 2026, conducted under SEBI regulations with current promoter shareholding at 51.82%.
06Apr 26
Aurobindo Pharma Board Approves Transfer of Domestic Branded Generic Business to Subsidiary
Aurobindo Pharma Limited's board approved the transfer of its domestic branded generic pharmaceutical formulations business to wholly owned subsidiary Auropharm Limited for INR 143.21 crores on April 6, 2026. The business contributed Rs. 1,753.40 million in turnover (0.55% of consolidated turnover) and will be transferred as a slump sale on going concern basis. The strategic move aims to consolidate domestic pharmaceutical operations under the subsidiary for enhanced operational efficiency, with completion expected within 90 to 120 days.
31Mar 26
Aurobindo Pharma Extends Solar Acquisition Timeline to June 2026
Aurobindo Pharma has extended its timeline for completing the acquisition of up to 26% stake in Swarnaakshu Solar Power Private Limited to June 30, 2026, due to pending state government approval for the captive solar power plant project. The company has been regularly updating stock exchanges about this strategic renewable energy investment since February 2025.
30Mar 26
Aurobindo Pharma Shareholders Approve Independent Director Appointment with 98.96% Majority
Aurobindo Pharma Limited successfully concluded its postal ballot process with shareholders approving Dr. Punita Kumar Sinha's appointment as Independent Director with 98.96% majority. The remote e-voting process from February 27 to March 28, 2026, saw 88.40% voter turnout with 513,445,001 votes polled out of 580,801,623 total shares. Dr. Sinha will serve as Independent Director for three years from February 9, 2026 to February 8, 2029, not liable to retire by rotation.
27Mar 26
Aurobindo Pharma Subsidiary CuraTeQ Biologics Partners with STADA for EU Markets
Aurobindo Pharma's wholly owned subsidiary CuraTeQ Biologics has formed a strategic partnership with STADA Arzneimittel AG for marketing and distribution of two EMA-approved biosimilars in key European markets including France and Germany. The agreement enables CuraTeQ to leverage STADA's established distribution network while creating new brand names for each biosimilar to optimize market positioning in the respective territories.
25Mar 26
UBS Raises Aurobindo Pharma Target Price to Rs 1400 Amid Balanced Risk-Reward Outlook
UBS has raised Aurobindo Pharma's target price to Rs 1400 from Rs 1200 while maintaining a neutral rating, citing balanced risk-reward dynamics. The brokerage noted the company's moderated US base business and gradual diversification strategy, including the inspection of Eugia III facility. However, UBS expects meaningful contribution from diversification efforts only from FY28-29, supporting their cautious outlook despite the price target increase.
20Mar 26
Aurobindo Pharma's Apitoria Unit Receives VAI Classification from USFDA
Aurobindo Pharma announced that its wholly owned subsidiary Apitoria Pharma's Unit-V API manufacturing facility in Telangana received VAI classification from USFDA. The inspection conducted from December 1-12, 2025 resulted in Form 483 with three observations, and the company has now received the Establishment Inspection Report confirming the VAI status with the inspection officially closed.
18Mar 26
US FDA Issues Form 483 With 9 Observations to Aurobindo Pharma's Eugia Unit
Aurobindo Pharma received FDA Form 483 with 9 observations for its Eugia Pharma Unit-II facility in Bhiwadi, Rajasthan, following November inspection. The FDA classified the facility as 'Official Action Indicated', requiring formal corrective response, though the company anticipates no immediate business impact.
13Mar 26
Aurobindo Pharma Faces Confirmed GST Demand of Rs. 77.61 Crore from Tax Authorities
Aurobindo Pharma Limited faces a confirmed GST demand of Rs. 77.61 crore plus equal penalty from tax authorities for alleged excess IGST refunds and compliance violations during 2017-2020. The company has paid Rs. 23.71 crore under protest and reversed Rs. 8.78 crore in ITC. While maintaining no material financial impact, the pharmaceutical company plans to appeal the decision at the GST Appellate Tribunal.
12Mar 26
Aurobindo Pharma's APL Healthcare Unit-IV Receives VAI Classification Following US FDA Inspection
Aurobindo Pharma announced that its wholly owned subsidiary APL Healthcare's Unit-IV facility in Andhra Pradesh has received VAI classification from the US FDA following a 10-day inspection in December 2025. The facility received an official Establishment Inspection Report confirming the VAI status with five observations noted, and the inspection is now officially closed.
04Mar 26
Eugia Pharma Launches Generic Pomalidomide Capsules as First-to-File Applicant
Eugia Pharma Specialities Limited, Aurobindo Pharma's wholly owned subsidiary, has launched pomalidomide capsules in multiple strengths as a First-to-File ANDA applicant for the generic version of Pomalyst®. The product targets a US$ 3.3 billion market opportunity and will be manufactured at Eugia Unit-I facility.
02Mar 26
Aurobindo Pharma's P Sarath Chandra Reddy Discharged in Delhi Liquor Policy Case
Delhi court discharged Aurobindo Pharma's Non-Executive Director P Sarath Chandra Reddy and 22 others in the Delhi Liquor Policy case after finding no evidence of conspiracy or corruption. The company issued official clarification under SEBI regulations confirming complete discharge from all CBI charges.
02Mar 26
US FDA Completes Inspection of Aurobindo Pharma's Eugia Unit with Four Observations
The US FDA has completed its inspection of Aurobindo Pharma's subsidiary Eugia Pharma Specialties Unit I manufacturing facility in Telangana, resulting in four regulatory observations. The company has committed to respond within FDA timelines and confirmed no impact on operations or financials.
26Feb 26
Eugia Pharma Receives USFDA Approval for Everolimus Tablets Across Multiple Dosages
Aurobindo Pharma's wholly owned subsidiary Eugia Pharma Specialities Limited has secured USFDA approval for Everolimus Tablets across four dosage strengths, bioequivalent to Novartis' Zortress Tablets. The approval targets a US$ 78 million market opportunity with commercial launch planned for Q1 FY27, marking the 184th ANDA approval for the Eugia Pharma Specialities Group facilities.
25Feb 26
Aurobindo Pharma Sees ₹107.01 Crore Block Trade on NSE
Aurobindo Pharma Limited executed a significant block trade on NSE worth ₹107.01 crores, involving 883,262 shares at ₹1211.50 per share. The transaction represents substantial institutional activity in the pharmaceutical company's stock through the block trade mechanism.
24Feb 26
Aurobindo Pharma Incorporates New Wholly Owned Subsidiary Engenra Biologics Private Limited
Aurobindo Pharma Limited incorporated Engenra Biologics Private Limited as a wholly owned subsidiary on February 24, 2026, with an initial share capital of Rs. 10 lakhs comprising 1,00,000 equity shares of Rs. 10 each. The subsidiary, established through 100% cash subscription, aims to expand contract manufacturing and pharmaceutical manufacturing operations. No regulatory approvals were required for the incorporation, and the new entity operates as a related party within the pharmaceuticals industry.
24Feb 26
Aurobindo Pharma Issues Postal Ballot Notice for Independent Director Appointment
Aurobindo Pharma Limited has issued a postal ballot notice seeking shareholder approval for appointing Dr. Punita Kumar Sinha as Independent Director for a three-year term from February 9, 2026 to February 8, 2029. The remote e-voting period runs from February 27, 2026 to March 28, 2026, with February 20, 2026 as the cut-off date for voting eligibility. Dr. Sinha brings over three decades of capital markets experience and previously served as Senior Managing Director at Blackstone Asia Advisors.
19Feb 26
Aurobindo Pharma Faces ₹169.84 Crore GST Demand Over Alleged Erroneous Refunds
Aurobindo Pharma faces a ₹169.84 crore GST demand from the Additional Commissioner of Central Tax, Ranga Reddy GST Commissionerate, over alleged erroneous ITC refunds from its EOU Unit 3 during September-December 2022. The disputed amount includes ₹84.92 crore in GST and an equal penalty. The company maintains no material financial impact and will appeal the decision, citing pending Writ Petitions in Telangana High Court and favorable Karnataka High Court precedent in similar cases.
18Feb 26
Aurobindo Pharma Clarifies US FDA Inspection Status Following Stock Exchange Queries
Aurobindo Pharma Limited issued a clarification to NSE and BSE on February 18, 2026, regarding news reports about a US FDA inspection at Unit-VII. The company confirmed it had previously disclosed the inspection completion on February 10, 2026, and emphasized its compliance with SEBI disclosure regulations. The pharmaceutical company stated that routine regulatory inspections are part of normal operations and that all material information has been adequately disclosed to exchanges.
16Feb 26
Aurobindo Pharma Reports Strong Q3FY26 Performance with 8.4% Revenue Growth
Aurobindo Pharma reported strong Q3FY26 results with 8.4% YoY revenue growth to Rs. 8,646 crores and EBITDA of Rs. 1,773 crores at 20.5% margin. European business led growth with 27% YoY increase to Rs. 2,703 crores, while US operations remained stable with injectable sales growing 17% YoY. The company's Pen-G facility ramped up production to 10,000 MT annually, benefiting from government's MIP policy on key antibiotics. Management expressed confidence in achieving higher-end EBITDA margins of 20-21% for FY26.
13Feb 26
Aurobindo Pharma's Subsidiary Acrotech Receives FDA Approval for ADQUEY Ointment for Atopic Dermatitis Treatment
Acrotech Biopharma Inc., a wholly owned step-down subsidiary of Aurobindo Pharma Limited, received US FDA approval on February 13, 2026, for ADQUEY (difamilast 1%) ointment to treat mild-to-moderate atopic dermatitis in adults and pediatric patients aged 2 and older. The novel, non-steroidal, topical PDE4 inhibitor was developed in collaboration with Otsuka Pharmaceutical and demonstrated superior efficacy in Phase III trials. This approval provides a new treatment option for millions of Americans with atopic dermatitis, with the most common adverse reaction being nasopharyngitis at 6%.
11Feb 26
Aurobindo Pharma Publishes Q3FY26 Results in Newspaper Advertisement
Aurobindo Pharma formally published its Q3FY26 unaudited financial results in Business Standard and Nava Telangana newspapers on February 11, 2026. The results demonstrate strong consolidated performance with total income of ₹86,459.0 million (8.36% YoY growth), net profit of ₹9,098.0 million, and earnings per share of ₹15.67, reflecting the company's robust operational performance.
02Feb 26
Aurobindo Pharma Schedules Q3FY26 Earnings Call for February 10, 2026
Aurobindo Pharma Limited has scheduled an earnings call for February 10, 2026 at 8:30 AM IST to discuss Q3FY26 unaudited financial results for the quarter and nine months ended December 31, 2025. The announcement was made under SEBI Regulation 30(2) requirements, with notifications sent to NSE and BSE. The call will be conducted via Zoom with mandatory pre-registration, and earnings presentation will be available on the company website post-announcement.
02Feb 26
Aurobindo Pharma Issues Fresh Clarification on Share Volume Movement Post-MIP Policy
Aurobindo Pharma provided updated clarification to stock exchanges on February 2, 2026, maintaining that significant trading volume movement continues to be market-driven following the government's January 29, 2026 MIP notification on Penicillin-G and related compounds. The company emphasized that information was already in public domain through DGFT website and reaffirmed regulatory compliance with no pending announcements.
23Jan 26
Aurobindo Pharma Establishes Wholly Owned Subsidiary in Philippines for Business Expansion
Aurobindo Pharma Limited has incorporated Aurobindo Pharma Philippines Inc. as a wholly owned subsidiary through Helix Healthcare B.V. on January 23, 2026. The new entity was established with an initial share capital of PESO 120,000,000 (approximately ₹17.00 crores) to expand pharmaceutical business operations in the Philippines market. The incorporation required no regulatory approvals and represents a strategic expansion move in the Southeast Asian pharmaceutical sector.
23Jan 26
Aurobindo Pharma shares fall 2.02% as stock trades among top losers on Nifty Midcap 150
Aurobindo Pharma shares fell 2.02% to ₹1,122.20, ranking among top losers on Nifty Midcap 150. The pharmaceutical company reported revenue growth of 9.38% to ₹31,723 crores in March 2025, with quarterly performance showing positive momentum in sales and net profit. Despite revenue growth, the company's net profit of ₹3,515 crores remained below historical peaks, while cash flow from operations improved significantly to ₹3,924 crores.
13Jan 26
USFDA Approval for Advair Generic Creates Mixed Impact for Aurobindo Pharma and Cipla
Respirent Pharmaceuticals and Lannett received USFDA approval for generic Advair Diskus, creating mixed implications for Indian pharma companies. Aurobindo Pharma benefits through its pending $250 million Lannett acquisition announced in July 2025, expected to close within two months. The approval strengthens Aurobindo's respiratory portfolio if the acquisition includes this newly approved product. However, increased competition poses challenges for Cipla, which filed its Advair generic application in 2020 and awaits approval, with estimated peak sales of $100 million and potential launch in second half of FY27.
13Jan 26
Respirent and Lannett Secure Final FDA Approval for Generic Advair Asthma Treatment
Respirent and Lannett have received final FDA approval for their generic Advair medication, used to treat asthma in patients aged four and older. This regulatory milestone enables commercial launch of the generic alternative and introduces additional competition in the respiratory medication market. The development has implications for pharmaceutical companies including Aurobindo Pharma and Cipla, potentially affecting market dynamics in the asthma treatment segment.
13Jan 26
Respirent and Lannett Secure FDA Approval for Generic Advair Asthma Treatment
Respirent and Lannett have received final approval for their generic Advair formulation, used for treating asthma in patients aged four and older. This regulatory milestone benefits associated pharmaceutical companies Aurobindo Pharma and Cipla, creating opportunities in the respiratory therapeutics market. The approval enhances treatment accessibility by providing a cost-effective alternative to branded asthma medications for pediatric and adult patients.
09Jan 26
Aurobindo Pharma's CuraTeQ Biologics Receives Health Canada Approval for Cancer Drug Biosimilar Dyrupeg
Aurobindo Pharma's subsidiary CuraTeQ Biologics has received Notice of Compliance from Health Canada's Biologics and Radiopharmaceutical Drugs Directorate for Dyrupeg, a pegylated filgrastim biosimilar. The drug is indicated for cancer patients with neutropenia, a condition involving low levels of neutrophils, which are essential white blood cells for immune function. This regulatory approval allows CuraTeQ Biologics to market the biosimilar treatment in Canada, strengthening Aurobindo Pharma's oncology portfolio in international markets.
09Jan 26
Aurobindo Pharma's CuraTeQ Biologics Receives Health Canada Approval for Dyrupeg Biosimilar
Aurobindo Pharma's biologics subsidiary CuraTeQ Biologics received Health Canada's Notice of Compliance for biosimilar product Dyrupeg on January 9, marking a key regulatory milestone. The approval confirms the product meets safety, efficacy and quality standards. The company recently acquired Khandelwal Laboratories' business for ₹325 crores and terminated a biosimilar partnership with BioFactura as part of portfolio prioritisation.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Zydus Life Science
Cipla
Laurus Labs
Dr Reddys LaboratoriesAurobindo Pharma
Lupin
Mankind Pharma
1,840.00
(-1.13%)
9,322.00
(-1.23%)
4,965.50
(+0.72%)
1,119.10
(+0.12%)
1,366.00
(-0.53%)
1,969.00
(+1.23%)
1,165.50
(+1.97%)
1,679.80
(+0.68%)
2,095.00
(+0.83%)
2,280.00
(+1.86%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
